How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...

China’s nascent weight loss drug market is poised for rapid growth ... it appeared just as effective as Lilly’s bestselling Zepbound in helping patients lose weight. The treatment also reduced liver ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...

According to Bloomberg Intelligence analysts, the drug could reach sales of $1.3 billion in the country by 2030, given its comparable weight-loss rate to Lilly's blockbuster Zepbound (tirzepatide), a ...